Galen E. B. Wright

Galen E. B. Wright

Auto-generated profile, based on publicly available information

Galen E. B. Wright

Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2016 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
GWG E B Wright
G E B Wright
BCBruce Carleton
Bruce Carleton
MHMichael R. Hayden
Michael R. Hayden
CRC J D Ross
C J D Ross
Differences in response to medications have a strong genetic component. By leveraging publically available data, the spectrum of such genomic variation can be investigated extensively. Pharmacogenomic variation was extracted from the 1000 Genomes Project Phase 3 data (2504 individuals, 26 global populations). A total of 12 084 genetic variants were found in 120 pharmacogenes, with the majority (90.0%) classified as rare variants (global minor allele frequency <0.5%), with 52.9% being singletons. Common variation clustered individuals into continental super-populations and 23 pharmacogenes contained highly differentiated variants (FST>0.5) for one or more super-population comparison. A median of three clinical variants (PharmGKB level 1A/B) was found per individual, and 55.4% of individuals carried loss-of-function variants, varying by super-population (East Asian 60.9%>African 60.1%>South Asian 60.3%>European 49.3%>Admixed 39.2%). Genome sequencing can therefore identify clinical pharmacogenomic variation, and future studies need to consider rare variation to understand the spectrum of genetic diversity contributing to drug response.

28 May 2013 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
GWGalen Eb Wright
Galen Eb Wright
PKPieter Gj Koornhof
Pieter Gj Koornhof
AAAdebowale A Adeyemo
Adebowale A Adeyemo
NTNicki Tiffin
Nicki Tiffin
Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Over the next five years, the Human Heredity and Health in Africa (H3Africa) Initiative, funded by the Wellcome Trust (United Kingdom) and the National Institutes of Health (United States of America), will contribute greatly towards sequencing of numerous African samples for biomedical research.

20 February 2018 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
CKChris Kay
Chris Kay
JCJennifer A. Collins
Jennifer A. Collins
GWGalen E.B. Wright
Galen E.B. Wright
FBFiona Baine
Fiona Baine
ZMZosia Miedzybrodzka
Zosia Miedzybrodzka
MHMichael R. Hayden
Michael R. Hayden

12 July 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GWGalen E.B. Wright
Galen E.B. Wright
UAUrsula Amstutz
Ursula Amstutz
BDBritt Drogemoller
Britt Drogemoller
JSJoanne Shih
Joanne Shih
SRShahrad Rod Rassekh
Shahrad Rod Rassekh
TCThe Canadian Pharmacogenomics Network for Drug Safety Consortium
The Canadian Pharmacogenomics Network for Drug Safety Consortium
Vincristine is an effective chemotherapeutic drug for various cancers, including acute lymphoblastic leukemia (ALL). Unfortunately, clinical utility is restricted by dose‐limiting vincristine‐induced peripheral neuropathies (VIPN). We sought to determine the association of VIPN with a recently identified risk variant, CEP72 rs924607, and drug absorption, distribution, metabolism, and excretion (ADME) gene variants in pediatric ALL. This was followed by a meta‐analysis of pharmacogenomic data from over 500 patients. CEP72 rs924607 was significantly associated with VIPN (P = 0.02; odds ratio (OR) = 3.4). ADME analyses identified associations between VIPN and ABCC1 rs3784867 (P = 5.34 × 10−5; OR = 4.9), and SLC5A7 rs1013940 (P = 9.00 × 10−4; OR= 8.6); genes involved in vincristine transport and inherited neuropathies, respectively. Meta‐analysis identified an association with a variant related to TTPA (rs10504361: P = 6.85 × 10−4; OR = 2.0), a heritable neuropathy‐related gene. This study provides essential corroboratory evidence for CEP72 rs924607 and highlights the importance of drug transporter and inherited neuropathy genes in VIPN.

1 September 2011 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
LWLouise Warnich
Louise Warnich
BDBritt Drogemoller
Britt Drogemoller
Michael Sean PepperMichael Sean Pepper
Michael Sean Pepper
Collet DandaraCollet Dandara
Collet Dandara
GWGalen E.B. Wright
Galen E.B. Wright
Abstract: South Africa, like many other developing countries, stands to benefit from novel diagnostics and drugs developed by pharmacogenomics guidance due to high prevalence of disease burden in the region. This includes both communicable (e.g., HIV/AIDS and tuberculosis) and non-communicable (e.g., diabetes and cardiovascular) diseases. For example, although only 0.7% of the worlds population lives in South Africa, the country carries 17% of the global HIV/AIDS burden and 5% of the global tuberculosis burden. Nobel Peace Prize Laureate Archbishop Emeritus Desmond Tutu has coined the term Rainbow Nation, referring to a land of wealth in its many diverse peoples and cultures. It is now timely and necessary to reflect on how best to approach new genomics biotechnologies in a manner that carefully considers the public health needs and extant disease burden in the region. The aim of this paper is to document and review the advances in pharmacogenomics in South Africa and importantly, to evaluate the direction that future research should take. Previous research has shown that the populations in South Africa exhibit unique allele frequencies and novel genetic variation in pharmacogenetically relevant genes, often differing from other African and global populations. The high level of genetic diversity, low linkage disequilibrium and the presence of rare variants in these populations question the feasibility of the use of current commercially available genotyping platforms, and may partially account for genotypephenotype discordance observed in past studies. However, the employment of high throughput technologies for genomic research, within the context of large clinical trials, combined with interdisciplinary studies and appropriate regulatory guidelines, should aid in acceleration of pharmacogenomic discoveries in high priority therapeutic areas in South Africa. Finally, we suggest that projects such as the H3Africa Initiative, the SAHGP and PGENI should play an integral role in the coordination of genomic research in South Africa, but also other African countries, by providing infrastructure and capital to local researchers, as well as providing aid in addressing the computational and statistical bottlenecks encountered at present.

1 November 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
BDBritt Drogemoller
Britt Drogemoller
JMJose G. Monzon
Jose G. Monzon
ABAmit P. Bhavsar
Amit P. Bhavsar
ABAdrienne E. Borrie
Adrienne E. Borrie
BBBeth Brooks
Beth Brooks
BCBruce Carleton
Bruce Carleton
Cisplatin, a chemotherapeutic agent used in the management of several cancers, is a key component in the treatment of testicular cancer—the most common malignancy among young men. Unfortunately, the use of this drug is complicated by the development of high-frequency hearing loss, which occurs in 20% to 40% of patients with testicular cancer treated with cisplatin.1